: RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range


RayzeBio Inc. RYZB, +33.33% has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company’s upsized initial public offering priced at the top end of the expected range. The company said it offered 17.28 million shares in the IPO, up from previous expectations of 14.4 million shares, to raise $311.0 million. The IPO priced late Thursday at $18, compared with previous expectations of a pricing between $16 and $18 a share. With 55.36 million shares outstanding expected after the IPO, the pricing values RayzeBio at $995.7 million. The stock is expected to begin trading on the Nasdaq after Friday’s open under the ticker symbol “RYZB.” The company is going public at a time of growing investor interest in IPOs, as semiconductor-design company Arm Holdings PLC’s stock ARM, -4.47% soared on its debut and as grocery-delivery app Instacart CART, raised the expected pricing range of its IPO. The Renaissance IPO ETF IPO, -0.96% has run up 34.6% year to date while the S&P 500 SPX, -1.22% has gained 17.3%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleThe Human Cost: Meet the brave Americans buying and selling their homes, despite stubbornly high interest rates
Next article: National flood-insurance program is set to expire — and could leave millions of homeowners in the lurch


Please enter your comment!
Please enter your name here